A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O’Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. ConnollyElad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)'. Together they form a unique fingerprint.

Medicine & Life Sciences